[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-340447-105":59,"doc-detail-340447-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","dna-repair-dependent-immunogenic-liabilities-in-colorectal-cancer-opportunities-from-errors","DNA repair-dependent immunogenic liabilities in colorectal cancer - opportunities from errors","","Colorectal cancer (CRC) remains a leading cause of cancer mortality, yet immunotherapy is ineffective for most patients. This review explains how vulnerabilities in DNA repair pathways can create both cell-autonomous and immune-related weaknesses. In CRC, mismatch repair defects generate neoantigens and type I interferon signaling, supporting immune checkpoint blockade. Homologous recombination defects induce genome instability and telomere alterations, rationalizing PARP inhibition, while ATR and other DDR inhibitors show activity beyond MMR status. The review aims to define how preexisting or induced DDR liabilities can enhance tumor sensitivity to immune-based therapies.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/dna-repair-dependent-immunogenic-liabilities-in-colorectal-cancer-opportunities-from-errors/340447/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/dna-repair-dependent-immunogenic-liabilities-in-colorectal-cancer-opportunities-from-errors/340447.png","ImageObject",300,407,{"name":92,"@type":93},"Quinn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is mismatch repair deficiency important for colorectal cancer immunotherapy?","Question",{"text":112,"@type":113},"Mismatch repair (MMR) defects lead to high neoantigen loads and activate type I interferon responses. MMR-deficient tumors show high response rates to immune checkpoint blockade such as pembrolizumab.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How do homologous recombination defects support the use of PARP inhibitors in CRC?",{"text":117,"@type":113},"Homologous recombination (HR) defects cause genome instability and telomere alterations, and they enable synthetic lethality with PARP1 inhibition. PARP blockade generates DNA single-strand breaks that can progress to double-strand breaks, promoting cancer cell death.",{"name":119,"@type":110,"acceptedAnswer":120},"What is the review’s main goal regarding DNA repair vulnerabilities in CRC?",{"text":121,"@type":113},"To clarify how preexisting or induced vulnerabilities in DNA repair pathways can be leveraged to increase colorectal tumor sensitivity to immune-based therapies.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},340447,1790189396,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962075114765,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","[www.nature.com/bjc](www.nature.com/bjc British)[ British](www.nature.com/bjc British) Journal of Cancer  \nREVIEW ARTICLE OPEN   \nGenetics and Genomics  \nDNA repair-dependent immunogenic liabilities in colorectal cancer: opportunities from errors  \nV. Amodio1,2,4, P. P. Vitiello 1,2,4, A. Bardelli 1,2 ✉ and G. Germano 1,3 ✉  \n© The Author(s) 2024  \n|  |  |  |\n| --- | --- | --- |\n|  | Colorectal cancer (CRC) remains one of the major causes of cancer death worldwide. Chemotherapy continues to serve as the primary treatment modality, while immunotherapy is largely ineffective for the majority of CRC patients. Seminal discoveries have emphasized that modifying DNA damage response (DDR) mechanisms confers both cell-autonomous and immune-related vulnerabilities across various cancers. In CRC, approximately 15% of tumours exhibit alterations in the mismatch repair (MMR) machinery, resulting in a high number of neoantigens and the activation of the type I interferon response. These factors, in conjunction with immune checkpoint blockades, collectively stimulate anticancer immunity. Furthermore, although less frequently, somatic alterations in the homologous recombination (HR) pathway are observed in CRC; these defects lead to genome instability and telomere alterations, supporting the use of poly (ADP-ribose) polymerase (PARP) inhibitors in HR-deﬁcient CRC patients. Additionally, other DDR inhibitors, such as Ataxia Telangiectasia and Rad3-related protein (ATR) inhibitors, have shown some efﬁcacy both in preclinical models and in the clinical setting, irrespective of MMR proﬁciency. The aim of this review is to elucidate how preexisting or induced vulnerabilities in DNA repair pathways represent an opportunity to increase tumour sensitivity to |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| immune-based therapies in CRC. |  |  |\n|  | British Journal of Cancer (2024) 131:1576–1590; [https://doi.org/10.1038/s41416-024-02848-8](https://doi.org/10.1038/s41416-024-02848-8) |  |\n|  |  |  |\n\nINTRODUCTION  \nDNA repair mechanisms are central to suppressing tumour onset by restricting the emergence of mutations due to physiological DNA replication and/or caused by endogenous and exogenous sources of DNA damage [1] . The inactivation of DNA repair mechanisms is associated with cancer initiation and progression in many types of cancer [1, 2] . A subset of colorectal cancers (CRCs) is characterized by germline and/or somatic genetic defects in DNA damage response (DDR) genes. The prevalence of somatic DDR defects in colorectal cancer (CRC) ranges between 10 and 30%[3–5] and the prevalence of DDR gene alterations is affected by the side of the colon where the disease emerges. There is evidence that the histology and molecular and immunological landscapes of CRCs arising on the right or left side of the colon are distinct [6] .  \nIn CRC, mismatch repair (MMR) was the ﬁrst DNA repair pathway to be linked to prognosis and response to therapy [7] . Notably, genetic alterations and epigenetic silencing of genes belonging to the MMR machinery are frequent in CRCs, with 15% of cancers in stages I-III being MMR-deﬁcient (MMRd) . These tumours are associated with right-sided primary tumours, older age at diagnosis and female sex [8] . In the clinic, MMRd tumours exhibit high response rates to immune checkpoint blockade (ICB) . For  \nexample, pembrolizumab, an anti-programmed death 1 (PD-1) agent, has shown remarkable efﬁcacy in MMRd patients in whom two or more lines of treatment have failed [9] . In addition, pathogenic variants of other DDR pathways, such as homologous recombination (HR), are also frequent in CRC [5] . HR is a DNA repair process that provides high-ﬁdelity, template-dependent repair or tolerance of complex DNA damage, including DNA gaps, DNA double-strand breaks (DSBs), stalled replication forks and DNA interstrand crosslinks [10] . The contribution of HR alter","cbCaieRmDexH1cTp","https://ap.wps.com/l/cbCaieRmDexH1cTp","pdf",1162834,15,"English","# Introduction\n## DNA repair mechanisms in cancer\n## DDR defects in CRC and response to therapy\n## MMR and HR vulnerabilities for immunotherapy","[{\"question\":\"Why is mismatch repair deficiency important for colorectal cancer immunotherapy?\",\"answer\":\"Mismatch repair (MMR) defects lead to high neoantigen loads and activate type I interferon responses. MMR-deficient tumors show high response rates to immune checkpoint blockade such as pembrolizumab.\"},{\"question\":\"How do homologous recombination defects support the use of PARP inhibitors in CRC?\",\"answer\":\"Homologous recombination (HR) defects cause genome instability and telomere alterations, and they enable synthetic lethality with PARP1 inhibition. PARP blockade generates DNA single-strand breaks that can progress to double-strand breaks, promoting cancer cell death.\"},{\"question\":\"What is the review’s main goal regarding DNA repair vulnerabilities in CRC?\",\"answer\":\"To clarify how preexisting or induced vulnerabilities in DNA repair pathways can be leveraged to increase colorectal tumor sensitivity to immune-based therapies.\"}]","DNA repair-dependent immunogenic liabilities in colorectal cancer - opportunities from errors | PDF",1790036558,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/40ee4ddd440c1bdc113e8c3b28cd1877.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7f8557570df8c60b3f8564f9ff4a1b21.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c394ff5732fdf6c35fd5f52bb48f2247.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/637c66c82cda940839394305f6c2284c.webp",980,1301]